文献速递乳腺癌

剂量密集型辅助化疗用于绝经前乳腺癌患者:MIG1与GIM2两项III期研究的汇总分析

Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies.
PubMed 文献 · Eur J Cancer · 2016-12-10

该汇总分析纳入MIG1与GIM2两项随机III期研究共1549例绝经前乳腺癌患者,评估辅助剂量密集化疗的疗效及治疗诱导闭经风险。剂量密集化疗较标准间隔化疗显著改善总生存(HR 0.71,95%CI 0.54-0.95,p=0.021),且未增加治疗诱导闭经风险(OR 1.00,95%CI 0.80-1.25,p=0.989)。作者认为高危绝经前乳腺癌患者可考虑将剂量密集辅助化疗作为首选治疗。

要点

  • 剂量密集辅助化疗较标准间隔化疗显著改善绝经前乳腺癌患者总生存(HR 0.71,95%CI 0.54-0.95,p=0.021)。
  • 激素受体阳性与阴性亚组的汇总HR分别为0.78(95%CI 0.54-1.12)与0.65(95%CI 0.40-1.06),交互作用p=0.330。
  • 剂量密集化疗未增加治疗诱导闭经风险(OR 1.00,95%CI 0.80-1.25,p=0.989)。

核心结论

  • 作者认为,高危绝经前乳腺癌患者可考虑将剂量密集辅助化疗作为首选治疗。

研究设计与样本

  • 对MIG1与GIM2两项随机III期研究进行汇总分析,共纳入1549例绝经前乳腺癌患者。
  • MIG1研究将淋巴结阳性或高危淋巴结阴性患者随机分配至每2周(剂量密集)或每3周(标准间隔)方案,共6周期氟尿嘧啶/表柔比星/环磷酰胺。
  • GIM2研究将淋巴结阳性患者随机分配至剂量密集或标准间隔的4周期EC或FEC,随后4周期剂量密集或标准间隔紫杉醇。
  • 利用个体患者数据,采用Cox比例风险模型计算总生存的HR,采用logistic回归模型计算治疗诱导闭经的OR。
  • 采用随机效应模型对两项研究进行Meta分析以计算参数估计值。

主要发现

  • 剂量密集化疗较标准间隔化疗显著改善总生存(HR 0.71,95%CI 0.54-0.95,p=0.021)。
  • 激素受体阳性患者的汇总HR为0.78(95%CI 0.54-1.12),激素受体阴性患者的汇总HR为0.65(95%CI 0.40-1.06),交互作用p=0.330。
  • 剂量密集化疗未观察到治疗诱导闭经风险增加(OR 1.00,95%CI 0.80-1.25,p=0.989)。

临床怎么用

  • 作者认为,高危绝经前乳腺癌患者可考虑将剂量密集辅助化疗作为首选治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: No evidence exists to recommend a specific chemotherapy regimen in young breast cancer patients. We performed a pooled analysis of two randomised clinical trials to evaluate the efficacy of adjuvant dose-dense chemotherapy in premenopausal breast cancer patients and its impact on the risk of treatment-induced amenorrhoea. PATIENTS AND METHODS: In the MIG1 study, node-positive or high-risk node-negative patients were randomised to 6 cycles of fluorouracil/epirubicin/cyclophosphamide every 2 (dose-dense) or 3 (standard-interval) weeks. In the GIM2 study, node-positive patients were randomised to 4 cycles of dose-dense or standard-interval EC or FEC followed by 4 cycles of dose-dense or standard-interval paclitaxel. Using individual patient data, the hazard ratio (HR) for overall survival by means of a Cox proportional hazards model and the odds ratio for treatment-induced amenorrhoea through a logistic regression model were calculated for each study. A meta-analysis of the two studies was performed using the random effect model to compute the parameter estimates. RESULTS: A total of 1,549 patients were included. Dose-dense chemotherapy was associated with a significant improved overall survival as compared to standard-interval chemotherapy (HR, 0.71; 95% confidence intervals [CI], 0.54-0.95; p = 0.021). The pooled HRs were 0.78 (95% CI, 0.54-1.12) and 0.65 (95% CI, 0.40-1.06) for patients with hormone receptor-positive and -negative tumours, respectively (interaction p = 0.330). No increased risk of treatment-induced amenorrhoea was observed with dose-dense chemotherapy (odds ratio, 1.00; 95% CI, 0.80-1.25; p = 0.989). CONCLUSION: Dose-dense adjuvant chemotherapy may be considered the preferred treatment option in high-risk premenopausal breast cancer patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Lambertini M, Ceppi M, Cognetti F, et al. Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. Eur J Cancer. 2016. PMID: 27951450. doi:10.1016/j.ejca.2016.10.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。